论文部分内容阅读
目的:探讨Skp2蛋白表达与上皮性卵巢癌发生、发展及预后评价的意义。方法:采用免疫组化法检测15例卵巢上皮性良性肿瘤、10例卵巢上皮性交界性肿瘤及58例上皮性卵巢癌中Skp2蛋白的表达情况。结果:Skp2在卵巢上皮性良性及交界性肿瘤中的表达均为阴性,而在上皮性卵巢癌中高表达,阳性率为48.28%(28/58),Skp2在中低分化组、Ⅲ/Ⅳ期组及有淋巴结转移组分别高于高分化组(P<0.01)、Ⅰ/Ⅱ期组(P<0.01)及无淋巴结转移组(P<0.01)。在不同年龄及组织类型的卵巢癌中表达无显著性差异。结论:Skp2在上皮性卵巢癌中表达,表达水平越高提示预后越差。
Objective: To investigate the significance of Skp2 protein expression and the occurrence, development and prognosis of epithelial ovarian cancer. Methods: The expression of Skp2 protein in 15 cases of ovarian epithelial benign tumor, 10 cases of ovarian epithelial borderline tumor and 58 cases of epithelial ovarian cancer were detected by immunohistochemistry. Results: Skp2 was negatively expressed in both benign and borderline ovarian tumors and highly expressed in epithelial ovarian cancer (48.28%, 28/58). Skp2 was positively expressed in moderately and poorly differentiated tumors and in stage Ⅲ / Ⅳ (P <0.01), Ⅰ / Ⅱ (P <0.01) and no lymph node metastasis (P <0.01), respectively. There was no significant difference in the expression of ovarian cancer of different age and type. Conclusion: Skp2 is expressed in epithelial ovarian cancer. The higher the expression level, the poorer the prognosis.